Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement

Sponsor
Swiss Cancer Institute
Study ID
NCT00003902
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
65 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of capecitabine and vinorelbine and to see how well they work in treating older women with metastatic breast cancer with or without bone involvement.

Key Dates

Start date
Mar 31, 1999
Status verified
May 2012
Primary completion
Dec 31, 2004
Completion
Sep 30, 2005

Study Design

Enrollment
110 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Maximum-tolerated dose (phase I)

Related Studies